Revenge Of The "Brain-Dead Kangaroos": Many Veterans Of 2007 Avandia Vote Come Down Harder On Drug In 2010
Executive Summary
Accumulating negative information about the cardiovascular risks of GlaxoSmithKline's type 2 diabetes drug Avandia (rosiglitazone) led a much larger number of FDA advisory panel members to recommend taking it off the market than when the same committees met three years earlier
You may also be interested in...
Avandia Advisory Committee Sees New Role For REMS As Research Tool
FDA advisory committee members who favor continued availability of GlaxoSmithKline's Avandia (rosiglitazone) with a Risk Evaluation and Mitigation Strategy seem to be hopeful the new regulatory tool can be used for an even broader purpose - providing answers needed to justify keeping the drug on the market
Avandia Advisory Committee Sees New Role For REMS As Research Tool
FDA advisory committee members who favor continued availability of GlaxoSmithKline's Avandia (rosiglitazone) with a Risk Evaluation and Mitigation Strategy seem to be hopeful the new regulatory tool can be used for an even broader purpose - providing answers needed to justify keeping the drug on the market
FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study
FDA's internal disagreements about the value of GlaxoSmithKline's RECORD trial stem, in part, from different visions of the role agency reviewers should play in analyzing data